ORIC Pharmaceuticals (NASDAQ:ORIC) Earns "Overweight" Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of ORIC Pharmaceuticals (NASDAQ:ORIC – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. Several other equities research analysts have also recently weighed in on the stock. JPMorgan Chase & Co. lowered their price target on shares of ORIC Pharmaceuticals from $19.00 […]

Related Keywords

United States , China , , Citigroup , China Universal Asset Management Co , Pharmaceuticals Daily , Cantor Fitzgerald , Pharmaceuticals Price Performance , Sherbrooke Park Advisers , Jpmorgan Chase Co , Algert Global , Pharmaceuticals Inc , Free Report , Get Free Report , Universal Asset Management , Park Advisers ,